Phase 1 VC005 PK, Renal Impairment vs Normal
ClinicalTrials.gov Studies
Summary
This is a Phase I, single-dose, open-label clinical trial (NCT07551570) evaluating the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with renal impairment compared to participants with normal renal function. The study, scheduled for April 27, 2026, plans to enroll approximately 24 participants across two cohorts under the condition of renal impairment. VC005 tablets is the investigational product under study.
“This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with renal impairment compared to participants with normal renal function.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This is a new clinical trial registration on ClinicalTrials.gov for a Phase I pharmacokinetic study of VC005 tablets. The study will enroll participants with varying degrees of renal impairment and matched participants with normal renal function to evaluate how renal function affects the drug's pharmacokinetic profile after a single 25 mg oral dose. Clinical trial registrations are informational records that do not create compliance obligations. Sponsors and clinical investigators should note this trial for competitive intelligence or patient recruitment purposes.
Pharmaceutical companies developing drugs with potential renal excretion should monitor studies like this as they may inform labeling requirements for renal dosing recommendations. Clinical research organizations may find this trial relevant for capacity planning. The trial's registration provides transparency about ongoing research but does not itself impose regulatory requirements on non-sponsor parties.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function
Phase 1 NCT07551570 Kind: PHASE1 Apr 27, 2026
Abstract
This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with renal impairment compared to participants with normal renal function.
Conditions: Renal Impairment
Interventions: VC005 Tablets
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.